BioPharma Credit

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and marketing pharmaceutical products for pain management and addiction medicine in the United States and internationally. The company utilizes its patented BioErodible MucoAdhesive (BEMA) technology, which consists of a small erodible polymer film designed for application to the buccal mucosa, to create effective drug delivery systems. Its product portfolio includes BELBUCA, a buprenorphine buccal film for chronic pain management; BUNAVAIL, a combination buccal film of buprenorphine and naloxone for treating opioid dependence; and ONSOLIS, a fentanyl buccal film for managing breakthrough pain in cancer patients. Additionally, BioDelivery Sciences offers Symproic, a medication for opioid-induced constipation in adults with chronic non-cancer pain. Founded in 1997 and headquartered in Raleigh, North Carolina, the company aims to address significant unmet medical needs in the therapeutic areas it serves.

Novocure Limited is an oncology company focused on developing and commercializing Tumor Treating Fields (TTFields) therapy for solid tumors. The company offers the Optune device, which delivers NovoTTF Therapy, a treatment that utilizes electric fields to disrupt the rapid division of cancer cells. This therapy is primarily used for adult patients with recurrent glioblastoma and is undergoing clinical trials for various other cancers, including brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. Novocure also collaborates with MSD to explore the combination of TTFields with KEYTRUDA, an anti-PD-1 therapy, and has a strategic partnership with NYU Grossman School of Medicine for preclinical and clinical research. Founded in 2000, Novocure is based in Saint Helier, Jersey, and has a significant presence in the United States, Europe, and Japan.